(Q36173574)

12 August 2017

1 reference

title

Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies (English)

1 reference

12 August 2017

Gregory S Friedrichs

1

1 reference

12 August 2017

Leslie Patmore

series ordinal

2

1 reference

12 August 2017

Alan Bass

series ordinal

3

1 reference

12 August 2017

publication date

1 July 2005

1 reference

Journal of Pharmacological and Toxicological Methods

12 August 2017

published in

1 reference

12 August 2017

volume

52

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

6-11

1 reference

Origins, practices and future of safety pharmacology

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

Drugs effects on ventricular repolarization: a critical evaluation of the strengths and weaknesses of current methodologies and regulatory practices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

ICH topic: the draft ICH S7B step 2: note for guidance on safety pharmacology studies for human pharmaceuticals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

The impact of drug-induced QT interval prolongation on drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

Safety pharmacology and risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2005.05.001

10.1016/J.VASCN.2005.05.001

7 January 2021

Identifiers

DOI

1 reference

12 August 2017

1 reference